1279082-99-3

Upstream product

• 1279082-98-2 3,6-di(3,4,5-trimethoxyphenyl)-1,2,4-triazine 
• 121-46-0 bicyclo[2.2.1]hepta-2,5-diene 
• 1136-86-3 methyl (3,4,5-trimethoxyphenyl) ketone 
• 51490-01-8 1-(3,4,5-trimethoxyphenyl)-2-bromoethanone 
• 624-28-2 2,5-dibromopyridine 
• 182163-96-8 3,4,5-trimethoxyphenylboronic Acid 

Downstream Products

• 1279083-00-9 2,5-bis(3,4,5-tris(dodecyloxy)phenyl)pyridine 

Relevant academic research and scientific papers

Columnar Iridium(III) Metallomesogens Based on Polycatenar Pyridyltetrazolate with Ambipolar Carrier Mobility Behavior

In this paper, we have designed and synthesized a series of neutral liquid-crystalline iridium(III) complexes based on polycatenar 2,5-diphenylpyridine and pyridyltetrazolate derivatives. Iridium(III) complexes all display highly emissive behavior with photoluminescence quantum yields in the range of 0.45-0.66 and a maximum emission wavelength at ～563 nm. Hexagonal columnar mesophases of iridium(III) complexes can be obtained by changing the number and length of peripheral alkoxyl chains attached to a 2,5-diphenylpyridine ligand (main ligand) and a pyridyltetrazolate ligand (auxiliary ligand). Moreover, experimental results of the charge transport properties for these iridium(III) complexes, which were measured by the space charge limited-current method, exhibit ambipolar carrier mobility behavior. In particular, the liquid-crystalline iridium(III) complexes can self-organize into one-dimensional (1D) nanostructure after thermal annealing treatment in their liquid-crystalline phase. The devices based on liquid crystal film display improved charge transport behavior compared with that of the devices based on polycrystalline film, indicating 1D nanostructure is beneficial to charge carrier injection and transportation.

ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER

Combretastatins analog compounds and their pharmaceutically acceptable salts are presented, as well as pharmaceutical compositions comprising the combretastatin analog compounds and uses of the combretastatin analog compounds, either alone or in combinati

Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents

A series of novel pyridine-bridged analogues of combretastatin-A4 (CA-4) were designed and synthesized. As expected, the 4-atom linker configuration retained little cytotoxicities in the compounds 2e, 3e, 3g, and 4i. Activities of the analogues with 3-atom linker varied widely depending on the phenyl ring substitutions, and the 3-atom linker containing nitrogen represents the more favorable linker structure. Among them, three analogues (4h, 4s, and 4t) potently inhibited cell survival and growth, arrested cell cycle, and blocked angiogenesis and vasculature formation in vivo in ways comparable to CA-4. The superposition of 4h and 4s in the colchicine-binding pocket of tubulin shows the binding posture of CA-4, 4h, and 4s are similar, as confirmed by the competitive binding assay where the ability of the ligands to replace tubulin-bound colchicine was measured. The binding data are consistent with the observed biological activities in antiproliferation and suppression of angiogenesis but are not predictive of their antitubulin polymerization activities.

LUMINOPHORES

There is described a non-planar iridium-ligand complex with accessible triplet states and a molecular structure that confers liquid-crystal like properties.

Emissive metallomesogens based on 2-phenylpyridine complexes of iridium(III)

Preparation of IrIII complexes using anisotropic 2,5-di(4-alkoxyphenyl)pyridine ligands leads to emissive, liquid-crystalline complexes containing bound Cl and dimethyl sulfoxide. Using analogous poly(alkoxy) ligands allows the preparation of bis(2-phenylpyridine)iridium(III) acac complexes, which are also mesomorphic. The observation of liquid crystallinity in octahedral complexes of this type is without precedent.(Figure Presented)